Trial · NCT01097616
Participant flow80
How many started, completed or left each group, period by period.
1 to 20 of 80
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-Blind (DB) Treatment (TRT) Phase | STARTED | Suvorexant Low Dose (LD) (TRT/Extension [EXT] Phase) | 254 | |
| Double-Blind (DB) Treatment (TRT) Phase | STARTED | Suvorexant High Dose (HD) (TRT/EXT Phase) | 383 | |
| Double-Blind (DB) Treatment (TRT) Phase | STARTED | Placebo (TRT/EXT Phase) | 385 | |
| Double-Blind (DB) Treatment (TRT) Phase | STARTED | Suvorexant LD (Run-out [RO], After Suvorexant LD in TRT/EXT) | 0 | |
| Double-Blind (DB) Treatment (TRT) Phase | STARTED | Placebo (RO, After Suvorexant LD in TRT/EXT) | 0 | |
| Double-Blind (DB) Treatment (TRT) Phase | STARTED | Suvorexant HD (RO, After Suvorexant HD in TRT/EXT) | 0 | |
| Double-Blind (DB) Treatment (TRT) Phase | STARTED | Placebo (RO, After Suvorexant HD in TRT/EXT) | 0 | |
| Double-Blind (DB) Treatment (TRT) Phase | STARTED | Placebo (RO, After Placebo in TRT/EXT) | 0 | |
| Double-Blind (DB) Treatment (TRT) Phase | Treated | Suvorexant Low Dose (LD) (TRT/Extension [EXT] Phase) | 254 | |
| Double-Blind (DB) Treatment (TRT) Phase | Treated | Suvorexant High Dose (HD) (TRT/EXT Phase) | 383 | |
| Double-Blind (DB) Treatment (TRT) Phase | Treated | Placebo (TRT/EXT Phase) | 384 | |
| Double-Blind (DB) Treatment (TRT) Phase | Treated | Suvorexant LD (Run-out [RO], After Suvorexant LD in TRT/EXT) | 0 | |
| Double-Blind (DB) Treatment (TRT) Phase | Treated | Placebo (RO, After Suvorexant LD in TRT/EXT) | 0 | |
| Double-Blind (DB) Treatment (TRT) Phase | Treated | Suvorexant HD (RO, After Suvorexant HD in TRT/EXT) | 0 | |
| Double-Blind (DB) Treatment (TRT) Phase | Treated | Placebo (RO, After Suvorexant HD in TRT/EXT) | 0 | |
| Double-Blind (DB) Treatment (TRT) Phase | Treated | Placebo (RO, After Placebo in TRT/EXT) | 0 | |
| Double-Blind (DB) Treatment (TRT) Phase | COMPLETED | Suvorexant Low Dose (LD) (TRT/Extension [EXT] Phase) | 230 | |
| Double-Blind (DB) Treatment (TRT) Phase | COMPLETED | Suvorexant High Dose (HD) (TRT/EXT Phase) | 345 | |
| Double-Blind (DB) Treatment (TRT) Phase | COMPLETED | Placebo (TRT/EXT Phase) | 341 | |
| Double-Blind (DB) Treatment (TRT) Phase | COMPLETED | Suvorexant LD (Run-out [RO], After Suvorexant LD in TRT/EXT) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01097616/flow